Predictive Value of Histological Grading Systems

  • D. F. Gleason


It has proved very difficult to determine the best treatment for prostatic cancer because of its unpredictable, variable and frequently prolonged course. Careful autopsy studies reveal many prostatic cancers, in steadily increasing incidence with age. Most of these were unsuspected and obviously did not need treatment. The increasing incidence with age tells us that many of them were present for many years. Thus, if the incidence of these unsuspected tumours is 10% at age 55, 20% at age 65 and 30% at age 75, then two-thirds of the tumours in the 75-year-old men must have been present for 10 years and one-third must have been present for 20 years! Many would have remained dormant but, unfortunately, they are also found in prostate tissue resected during life, causing a dilemma.


Histological Grade Radical Prostatectomy Cancer Death Rate Prostatic Adenocarcinoma Histological Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The Veterans Administration Cooperative Urological Research Group (1967) Carcinoma of the prostate: treatment comparisons. J Urol 98:516–522Google Scholar
  2. 2.
    Blackard C, Doe R, Mellinger G, Byar D (1970) Incidence of cardiovascular disease in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 26:249–256PubMedCrossRefGoogle Scholar
  3. 3.
    Byar D (1972) Treatment of prostatic cancer: studies by the VACURG. Bull NY Acad Med 48:751–766Google Scholar
  4. 4.
    Byar D (1973) The Veterans Administration Cooperative Urological Group’s studies of cancer of the prostate. Cancer 32:1126–1130PubMedCrossRefGoogle Scholar
  5. 5.
    Bailar JC, Mellinger GT, Gleason DF (1966) Survival rates of patients with prostatic cancer, tumor stage, and differentiation—preliminary report. Cancer Chemother Rep 50:129–136PubMedGoogle Scholar
  6. 6.
    Gleason DF, Mellinger GT, VACURG (1974) Prediction of prognosis for prostatic carcinoma by combined histological grading and clinical staging. J Urol 111:58–64PubMedGoogle Scholar
  7. 7.
    Gleason DF (1977) Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M (ed) Urologie pathology: the prostate. Lea and Febiger, Philadelphia, pp 171–197Google Scholar
  8. 8.
    Byar D, Corle D, VACURG (1981) VACURG randomized trial of radical prostatectomy for Stages I and II prostatic cancer. Urology 17 (Suppl): 7–11PubMedGoogle Scholar
  9. 9.
    Corriere J, Cornog J, Murphy J (1970) Prognosis in patients with carcinoma of the prostate. Cancer 25:911–918PubMedCrossRefGoogle Scholar
  10. 10.
    Paulson D, Piserchia P, Gardner W (1980) Predictors of lymphatic spread in prostatic adenocarcinoma. Uro-oncology Research Group study. J Urol 123:697–699PubMedGoogle Scholar
  11. 11.
    Kramer S, Spahr J, Brendler C, Glenn J, Paulson D (1980) Experience with Gleason’s histopathologic grading in prostatic cancer. J Urol 124:223–225PubMedGoogle Scholar
  12. 12.
    Thomas R, Lewis RW, Sarma DP, Coker GB, Rao MK, Robert JA (1982) Aid to accurate staging—histopathologic grading in prostatic cancer. J Urol 128:726–728PubMedGoogle Scholar
  13. 13.
    Luciani L, Piscioli F (1983) Accuracy of transcutaneous aspiration biopsy in the definitive assessment of nodal involvement in prostatic carcinoma. Br J Urol 55:321–325PubMedCrossRefGoogle Scholar
  14. 14.
    Piscioli F, Leonardi E, Reich A, Luciani L (1984) Percutaneous lymph node aspiration biopsy and tumor grade in staging of prostatic carcinoma. Prostate 5:459–468PubMedCrossRefGoogle Scholar
  15. 15.
    Oota K (1981) Pathomorphological studies on carcinoma of the prostate in Japan. Prostate 1:125–134CrossRefGoogle Scholar
  16. 16.
    Sogani PC, Israel A, Lieberman PH, Lesser M, Whitmore W (1985) Gleason grading of prostate cancer: a predictor of survival. Urology 25:223–227PubMedCrossRefGoogle Scholar
  17. 17.
    Department of Health, Education and Welfare Publication # (HRA) 75–110. US life tables 1969–1971Google Scholar
  18. 18.
    Sharkey FE (1982) Morphometric analysis of differentiation in human breast carcinoma. Tumor heterogeneity. Arch Pathol Lab Med 307:343–347Google Scholar
  19. 19.
    Broders AC (1926) Carcinoma. Grading and practical application. AMA Arch Pathol 2:376–381Google Scholar
  20. 20.
    Pierce GB, Wallace C (1971) Differentiation of malignant into benign cells. Cancer Res 31:127–134PubMedGoogle Scholar
  21. 21.
    Ross DW (1985) Leukemic cell maturation. Arch Pathol Lab Med 109:309–313PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • D. F. Gleason

There are no affiliations available

Personalised recommendations